登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov 上登记的一项多发性骨髓瘤开放试验,由中国医学科学院血液病医院(血液学研究所)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07726160,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 3
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(3 项)收起清单
18 岁 至 70 岁;性别:不限
登记记录的入选字段
Diagnosis of multiple myeloma (MM) confirmed per the IMWG diagnostic criteria. and presenting with relapsed/refractory (r/r) MM following at least ≥3 prior lines of therapy. Prior therapies must have included proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and/or CD38 monoclonal antibodies. While prior exposure to all three therapeutic classes is preferred, subjects must have received at least two of these treatment categories (PIs, IMiDs, and/or anti-CD38) during their prior therapy;
入选标准第 3 条
Subjects with r/r MM at screening, with documented disease progression, or who are considered refractory, either during or within 12 months after the most recent anti-myeloma treatment.
入选标准第 4 条
Male subjects with reproductive potential and female subjects of childbearing potential must agree to use effective contraceptive measures from the time of signing the informed consent form (ICF) through 1 year after administration of the study drug. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and prior to drug infusion, and must not be lactating.
入选标准第 10 条
Receipt of any type of T-cell engager (TCE) therapy within 8 weeks or 5 half-lives (whichever is shorter) prior to the first dose of the investigational drug.
排除标准第 2 条
Receipt of any of the following within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug:
排除标准第 3 条
Receipt of proteasome inhibitors, immunomodulatory agents, radiotherapy, or traditional Chinese medicine preparations approved for anti-tumor indications within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose of the investigational drug.
排除标准第 4 条
Receipt of allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 6 months prior to infusion, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months prior to infusion.
排除标准第 6 条
Presence of active second primary malignancies, with the following exceptions: malignancies that have received curative treatment with no known active disease for ≥2 years prior to enrollment; or adequately treated non-melanoma skin cancer with no current evidence of disease.
排除标准第 7 条
Major surgery within 2 weeks prior to study drug administration, or planned major surgery within 2 weeks after study drug administration, excluding surgeries performed under local anesthesia.
排除标准第 13 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 , and an estimated life expectancy of ≥3 months.
入选标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07726160,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Subjects are eligible for inclusion only if they meet all of the following criteria: Age between 18 and 70 years (inclusive), regardless of gender; Diagnosis of multiple myeloma (MM) confirmed per the IMWG diagnostic criteria. and presenting with relapsed/refractory (r/r) MM following at least ≥3 prior lines of therapy. Prior therapies must have included proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and/or CD38 monoclonal antibodies. While prior exposure to all three therapeutic classes is preferred, subjects must have received at least two of these treatment categories (PIs, IMiDs, and/or anti-CD38) during their prior therapy; Subjects with r/r MM at screening, with documented disease progression, or who are considered refractory, either during or within 12 months after the most recent anti-myeloma treatment. The following cohort-specific criteria must be satisfied: Measurable disease at screening, meeting at least one of the following criteria: Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 , and an estimated life expectancy of ≥3 months. Bone marrow function test results meeting the following requirements: Adequate organ function, defined as: Male subjects with reproductive potential and female subjects of childbearing potential must agree to use effective contraceptive measures from the time of signing the informed consent form (ICF) through 1 year after administration of the study drug. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and prior to drug infusion, and must not be lactating. Subjects or their legally authorized representatives must agree to participate in this clinical trial and sign the informed consent form (ICF), indicating their understanding of the purpose and procedures of the trial and their willingness to participate in the study.排除标准:Exclusion Criteria:
Subjects meeting any of the following criteria will be excluded from enrollment in this study: Receipt of any type of T-cell engager (TCE) therapy within 8 weeks or 5 half-lives (whichever is shorter) prior to the first dose of the investigational drug. Receipt of any of the following within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of the investigational drug: Receipt of proteasome inhibitors, immunomodulatory agents, radiotherapy, or traditional Chinese medicine preparations approved for anti-tumor indications within 2 weeks or 5 half-lives (whichever is shorter) prior to the first dose of the investigational drug. Presence of meningeal, brainstem, or spinal cord metastasis and/or compression, or active central nervous system (CNS) metastasis. Receipt of allogeneic hematopoietic stem cell transplantation (allo-HSCT) within 6 months prior to infusion, or autologous hematopoietic stem cell transplantation (auto-HSCT) within 3 months prior to infusion. Presence of active second primary malignancies, with the following exceptions: malignancies that have received curative treatment with no known active disease for ≥2 years prior to enrollment; or adequately treated non-melanoma skin cancer with no current evidence of disease. Prior treatment with any agent pseudotyped with vesicular stomatitis virus G (VSVG). Presence of severe, uncontrolled active infection (bacterial, viral, fungal, etc.) at screening. Within 6 months prior to infusion: Presence of symptomatic heart failure or severe cardiac arrhythmias, including: Clinically significant comorbidities, including: Major surgery within 2 weeks prior to study drug administration, or planned major surgery within 2 weeks after study drug administration, excluding surgeries performed under local anesthesia. Uncontrolled hypertension, hypercalcemia, or diabetes mellitus. Administration of live attenuated vaccines within 1 month prior to study drug administration. Known severe hypersensitivity reaction to KIV-318 or its formulation components (e.g., protein components). Known severe hypersensitivity reaction to tocilizumab. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07726160, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07726160,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。